Scholar Rock Holding (SRRK) Accounts Payables (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Accounts Payables of $9.2 million for Q1 2026, up 107.75% year-over-year from $4.4 million in Q1 2025, and down 10.53% quarter-over-quarter from $10.3 million in Q4 2025.
Scholar Rock Holding (SRRK) Accounts Payables (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Accounts Payables history runs 10 years deep, the most recent figure standing at $9.2 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 107.75% year-over-year to $9.2 million; the TTM figure through Mar 2026 stood at $9.2 million (up 107.75% YoY), while the FY2025 annual figure was $10.3 million, up 2.06% from the prior year.
- Accounts Payables for Q1 2026 stood at $9.2 million, down from $10.3 million in the prior quarter.
- The five-year high for Accounts Payables was $10.3 million in Q4 2025, with the low at $1.1 million in Q2 2025.
- The 5-year median for Accounts Payables is $3.5 million (2023), against an average of $4.5 million.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables surged 191.34% in 2024, then tumbled 66.7% in 2025.
- Scholar Rock Holding's Accounts Payables stood at $4.0 million in 2022, then dropped by 13.24% to $3.5 million in 2023, then soared by 191.34% to $10.1 million in 2024, then grew by 2.06% to $10.3 million in 2025, then retreated by 10.53% to $9.2 million in 2026.
- Business Quant data shows SRRK's Accounts Payables at $9.2 million in Q1 2026, $10.3 million in Q4 2025, and $6.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | 11.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.00 Mn |
| Mar 31, 2026 | 9.22 Mn |
| Dec 31, 2025 | 10.30 Mn |
| Sep 30, 2025 | 6.77 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 4.44 Mn |
| Dec 31, 2024 | 10.10 Mn |
| Sep 30, 2024 | 4.07 Mn |
| Jun 30, 2024 | 3.32 Mn |
| Mar 31, 2024 | 2.87 Mn |
| Dec 31, 2023 | 3.47 Mn |
| Sep 30, 2023 | 1.97 Mn |
| Jun 30, 2023 | 3.04 Mn |
| Mar 31, 2023 | 3.72 Mn |
| Dec 31, 2022 | 3.99 Mn |
| Sep 30, 2022 | 2.00 Mn |
| Jun 30, 2022 | 2.85 Mn |
| Mar 31, 2022 | 2.99 Mn |
| Dec 31, 2021 | 4.43 Mn |
| Sep 30, 2021 | 2.04 Mn |